Navigation Links
Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings
Date:1/12/2009

NANJING, China, Jan. 12 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu (also known as Endostar) in China, today announced preliminary revenue and earnings for the full year of 2008.

Based upon preliminary data for the fourth quarter, Simcere expects the total revenue for the full year 2008 to be approximately RMB1.72 billion, within the previously stated range of RMB1.7 billion to RMB1.8 billion. The company now expects the range for the net income for the full year 2008 to be approximately 10% below the previously stated range of RMB390.0 million and RMB400.0 million.

The company noted that based on the available information, the lower than expected earnings were primarily due to: (1) the demand for drugs not covered by China's national, and some provincial, medical insurance declined in the fourth quarter as macro economic conditions impacted the ability of self-pay patients to afford such treatments. (2) the company's interest income and foreign exchange gain declined materially as compared to previous quarters.

The company noted that its normal year end financial reporting closing process is still underway and management will provide more information to investors during its regular quarterly conference call in March 2009.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007
2. Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions
3. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
4. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
5. Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
6. Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
7. Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources
8. Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008
9. Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase
10. Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/16/2017)... ... July 16, 2017 , ... OHAUS Corporation, a leading worldwide ... its new line of Extreme Environment Shakers today. , Extreme Environment Shakers , ... for optimal cell growth such as cell cultures, solubility studies and extraction procedures. ...
(Date:7/14/2017)... ... ... Dr. Joshua Mondlick has introduced the LANAP® protocol to treat gum disease and ... Phoenix area. Dr. Mondlick is at the forefront of the future of dentistry, ... bone and with significantly less pain than traditional surgery options. , “With traditional surgeries, ...
(Date:7/13/2017)... ... July 13, 2017 , ... Thousands of pilots from across ... the National Aeromodeling Championships (Nats). Pilots come to Muncie to compete in various categories ... on US teams that participate in world championships. , RC Pylon (July 14-21): One ...
(Date:7/13/2017)... Island, NY (PRWEB) , ... July 13, 2017 ... ... starting with only two spectrophotometer calibration standards. Blast forward seven years and ... covers photometric accuracy, holmium oxide for wavelength accuracy, and resolution testing. ...
Breaking Biology Technology:
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed ... received the prestigious international IAIR Award for the most innovative high security ... ... Maldives Immigration Controller General, ... picture on the right) have received the IAIR award for the "Most ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 8.8% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
(Date:3/22/2017)... LIVERMORE, Calif. , March 21, 2017 ... recognition analytics company serving law enforcement agencies, announced today ... Sheridan as director of public safety business development. ... of diversified law enforcement experience, including a focus on ... Vigilant. In his most recent position, Mr. Sheridan served ...
Breaking Biology News(10 mins):